{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:33:37Z","timestamp":1762104817201,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","amjmedsci.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.amjms.2024.04.019","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T12:30:26Z","timestamp":1714566626000},"page":"90-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Metformin as adjuvant treatment in hepatitis C virus infections and associated complications"],"prefix":"10.1016","volume":"368","author":[{"given":"Dylan","family":"Landis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachi","family":"Khemka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Busara","family":"Songtanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2024.04.019_bib0001","article-title":"Burden, outcome, and comorbidities of extrahepatic manifestations in hepatitis C virus infection","volume":"12","author":"Songtanin","year":"2022","journal-title":"Biology (Basel)"},{"issue":"5","key":"10.1016\/j.amjms.2024.04.019_bib0002","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/egh.09.41","article-title":"Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and type 2 diabetes mellitus","volume":"3","author":"Donadon","year":"2009","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.amjms.2024.04.019_bib0003","article-title":"Diabetes mellitus and risk of hepatic fibrosis\/cirrhosis","volume":"2019","author":"Li","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.amjms.2024.04.019_bib0004","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"10.1016\/j.amjms.2024.04.019_bib0005","first-page":"1848","article-title":"Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: a quasi-experimental study","volume":"67","author":"Khan","year":"2017","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.amjms.2024.04.019_bib0006","unstructured":"Centers for Disease Control and Prevention. Hepatitis C Surveillance 2021. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2021surveillance\/hepatitis-c.htm. accessed 3-24-2024."},{"key":"10.1016\/j.amjms.2024.04.019_bib0007","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2021. https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html. accessed 3-24-2024."},{"issue":"1","key":"10.1016\/j.amjms.2024.04.019_bib0008","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.gastro.2010.08.055","article-title":"Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C","volume":"140","author":"Rao","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.amjms.2024.04.019_bib0009","doi-asserted-by":"crossref","first-page":"746.e1","DOI":"10.1016\/j.amjmed.2016.12.029","article-title":"Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome","volume":"130","author":"Kasmari","year":"2017","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.amjms.2024.04.019_bib0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13063-016-1454-6","article-title":"Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial","volume":"17","author":"Doyle","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.amjms.2024.04.019_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.obmed.2020.100186","article-title":"Metformin: A review of its therapeutic efficacy and adverse effects","volume":"17","author":"Shurrab","year":"2020","journal-title":"Obesity Medicine"},{"issue":"6","key":"10.1016\/j.amjms.2024.04.019_bib0012","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.21037\/jtd-22-39","article-title":"The potential role for metformin in the prevention and treatment of tuberculosis","volume":"14","author":"Sutter","year":"2022","journal-title":"J Thorac Dis"},{"issue":"4","key":"10.1016\/j.amjms.2024.04.019_bib0013","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.amjms.2022.04.027","article-title":"The effect of metformin on glucose metabolism in patients receiving glucocorticoids","volume":"364","author":"Landis","year":"2022","journal-title":"Am J Med Sci"},{"issue":"10","key":"10.1016\/j.amjms.2024.04.019_bib0014","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1177\/1060028013503108","article-title":"Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C","volume":"47","author":"Harris","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"19","key":"10.1016\/j.amjms.2024.04.019_bib0015","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin in 2019","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.amjms.2024.04.019_bib0016","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.amjms.2024.04.019_bib0017","doi-asserted-by":"crossref","first-page":"E1555","DOI":"10.1152\/ajpendo.00622.2006","article-title":"AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells","volume":"292","author":"Krawiec","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.amjms.2024.04.019_bib0018","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.amjms.2024.04.019_bib0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev Cell"},{"issue":"4","key":"10.1016\/j.amjms.2024.04.019_bib0020","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.96.4.1603","article-title":"Target genes of \u03b2-catenin\u2013T cell-factor\/lymphoid-enhancer-factor signaling in human colorectal carcinomas","volume":"96","author":"Mann","year":"1999","journal-title":"Proc Nat Acad Sci"},{"issue":"4","key":"10.1016\/j.amjms.2024.04.019_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040790","article-title":"Additional inhibition of Wnt\/\u03b2-Catenin signaling by metformin in DAA treatments as a novel therapeutic strategy for HCV-infected patients","volume":"10","author":"Lin","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.amjms.2024.04.019_bib0022","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jhep.2013.06.025","article-title":"The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-\u03b2 signaling","volume":"59","author":"Goto","year":"2013","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.amjms.2024.04.019_bib0023","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj3550297","article-title":"Identification and characterization of a novel sucrose-non-fermenting protein kinase\/AMP-activated protein kinase-related protein kinase, SNARK","volume":"355","author":"Lefebvre","year":"2001","journal-title":"Biochem J"},{"issue":"35","key":"10.1016\/j.amjms.2024.04.019_bib0024","doi-asserted-by":"crossref","first-page":"15541","DOI":"10.1073\/pnas.1008131107","article-title":"Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle","volume":"107","author":"Koh","year":"2010","journal-title":"Proc Nat Acad Sci"},{"issue":"25","key":"10.1016\/j.amjms.2024.04.019_bib0025","doi-asserted-by":"crossref","first-page":"11549","DOI":"10.1073\/pnas.0912426107","article-title":"Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase","volume":"107","author":"Mankouri","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.amjms.2024.04.019_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191805","article-title":"Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy","volume":"13","author":"Del Campo","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.amjms.2024.04.019_bib0027","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1631\/jzus.B2100910","article-title":"Translationally controlled tumor protein: the mediator promoting cancer invasion and migration and its potential clinical prospects","volume":"23","author":"Gao","year":"2022","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.amjms.2024.04.019_bib0028","doi-asserted-by":"crossref","unstructured":"Bommer U.A. The translational controlled tumour protein TCTP: biological functions and regulation. results probl cell differ 2017;64:69\u2013126. DOI: 10.1007\/978-3-319-67591-6_4.","DOI":"10.1007\/978-3-319-67591-6_4"},{"issue":"11","key":"10.1016\/j.amjms.2024.04.019_bib0029","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-020-03149-7","article-title":"The mRNA of TCTP functions as a sponge to maintain homeostasis of TCTP protein levels in hepatocellular carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis"},{"issue":"13","key":"10.1016\/j.amjms.2024.04.019_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137027","article-title":"Human protein tyrosine phosphatase 1B (PTP1B): from structure to clinical inhibitor perspectives","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjms.2024.04.019_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2323078","article-title":"Targeted inhibition of protein tyrosine phosphatase 1b by viscosol ameliorates type 2 diabetes pathophysiology and histology in diabetic mouse model","volume":"2022","author":"Sohail","year":"2022","journal-title":"Biomed Res Int"},{"issue":"23","key":"10.1016\/j.amjms.2024.04.019_bib0032","doi-asserted-by":"crossref","first-page":"19564","DOI":"10.1074\/jbc.M112.342709","article-title":"Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice","volume":"287","author":"Garc\u00eda-Ruiz","year":"2012","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.amjms.2024.04.019_bib0033","doi-asserted-by":"crossref","first-page":"e47904","DOI":"10.1371\/journal.pone.0047904","article-title":"The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance","volume":"7","author":"del Campo","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.amjms.2024.04.019_bib0034","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm2199","article-title":"Signal integration in the endoplasmic reticulum unfolded protein response","volume":"8","author":"Ron","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"40","key":"10.1016\/j.amjms.2024.04.019_bib0035","doi-asserted-by":"crossref","first-page":"30299","DOI":"10.1074\/jbc.M607007200","article-title":"Endoplasmic reticulum stress triggers autophagy","volume":"281","author":"Yorimitsu","year":"2006","journal-title":"J Biol Chem"},{"issue":"7182","key":"10.1016\/j.amjms.2024.04.019_bib0036","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.amjms.2024.04.019_bib0037","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol Rev"},{"issue":"18","key":"10.1016\/j.amjms.2024.04.019_bib0038","doi-asserted-by":"crossref","first-page":"12297","DOI":"10.1074\/jbc.M900573200","article-title":"ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy","volume":"284","author":"Ganley","year":"2009","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.amjms.2024.04.019_bib0039","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4161\/auto.22791","article-title":"Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy","volume":"9","author":"Huang","year":"2013","journal-title":"Autophagy"},{"issue":"54","key":"10.1016\/j.amjms.2024.04.019_bib0040","doi-asserted-by":"crossref","first-page":"91928","DOI":"10.18632\/oncotarget.20248","article-title":"Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase","volume":"8","author":"Tsai","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.amjms.2024.04.019_bib0041","first-page":"435","article-title":"The role of metformin in viral diseases","volume":"13","author":"Joshi","year":"2022","journal-title":"Sys Rev Pharm"},{"issue":"8","key":"10.1016\/j.amjms.2024.04.019_bib0042","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/jc.2010-2415","article-title":"Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients","volume":"96","author":"Nkontchou","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.amjms.2024.04.019_bib0043","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000282104","article-title":"Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management","volume":"28","author":"del Campo","year":"2010","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.amjms.2024.04.019_bib0044","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.23206","article-title":"Treatment of insulin resistance with metformin in na\u00efve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin","volume":"50","author":"Romero-G\u00f3mez","year":"2009","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.amjms.2024.04.019_bib0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jfma.2014.05.007","article-title":"A pilot study of add-on oral hypoglycemic agents in treatment-na\u00efve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin","volume":"113","author":"Hsu","year":"2014","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"10.1016\/j.amjms.2024.04.019_bib0046","doi-asserted-by":"crossref","first-page":"e14104","DOI":"10.1111\/ijcp.14104","article-title":"The potential hepatoprotective effect of metformin in hepatitis C virus-infected adolescent patients with beta thalassemia major: randomised clinical trial","volume":"75","author":"Abdel Monem","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.amjms.2024.04.019_bib0047","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/j.ijid.2012.02.004","article-title":"The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance","volume":"16","author":"Yu","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.amjms.2024.04.019_bib0048","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.amjms.2024.04.019_bib0049","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.amjms.2024.04.019_bib0050","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.32244","article-title":"Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease","volume":"75","author":"Kramer","year":"2022","journal-title":"Hepatol"},{"issue":"4","key":"10.1016\/j.amjms.2024.04.019_bib0051","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.amjms.2024.04.019_bib0052","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.amjms.2024.04.019_bib0053","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/hep.32434","article-title":"Risk factors for HCC in contemporary cohorts of patients with cirrhosis","volume":"77","author":"Kanwal","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.amjms.2024.04.019_bib0054","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2022.09.019","article-title":"Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan","volume":"78","author":"Tsai","year":"2023","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.amjms.2024.04.019_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/v15122451","article-title":"Metformin and hepatocellular carcinoma risk reduction in diabetic patients with chronic hepatitis C: fact or fiction?","volume":"15","author":"Sacco","year":"2023","journal-title":"Viruses"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924012138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924012138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T13:23:46Z","timestamp":1721654626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962924012138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0002962924012138"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2024.04.019","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin as adjuvant treatment in hepatitis C virus infections and associated complications","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2024.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}